Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
10/24/2024
NHSA to Initiate New Round of Negotiation for 2024 NRDL Listing
10/24/2024
Rouse: China's Rapid Rise in Global Innovation Strengthens Patent Syst...
10/24/2024
Beijing Biostar Advances Lead Oncology Asset with $41M Hong Kong IPO
10/24/2024
CASI Granted Chinese CTA Approval for CID-103 in Immune Thrombocytope...
10/24/2024
China's Innovative Drug Industry Faces Pricing Pressures Amid Steady D...
10/24/2024
U.S. and China Compete for Top Position in the Global Drug Development...
10/24/2024
Reinventing Your China Strategy: A Podcast Preview of the China Health...
10/24/2024
Patent Term Extensions In China: Overviews And Takeaways (Mondaq)
10/23/2024
Guangzhou Aims to Establish Itself as a Global Biopharmaceutical Hub
10/23/2024
China Recovers CNY 16B in Misused BMI Funds
10/22/2024
CDE Issues the Technical Requirements for the Pharmaceutical Research ...
10/22/2024
Everest Announces Positive Results of Chinese Subpopulation Data from ...
10/22/2024
Oricell's IND for MSLN/Claudin 18.2 Dual CAR-T Therapy Cleared in Chin...
10/22/2024
Bristol Ends LaNova Partnership on Claudin18.2 ADC, Eyes Potential I-M...
10/22/2024
siRNA Developer Rigerna Secures CNY100M+ in Series Angel+ Funding
10/22/2024
XellSmart RaisesCNY 100M+ in Series B1 Financing for iPS-Derived Cell ...
10/22/2024
Takeda: China to Emerge as Its Second-Largest Market by 2031
10/22/2024
ArkBio's Ziresovir Set to Transform RSV Treatment in China
10/21/2024
Novabio Completes Pre-Series A Financing to Accelerate Treg Cell Thera...
10/21/2024
Akeso Launches Phase 1/2 Trial for Novel Bispecific Antibody Combinati...
10/21/2024
BeiGene's Secures 14th Indication in China for Tislelizumab
10/21/2024
Innovent's IBI3001 Receives Approval for Clinical Trials in China for ...
10/21/2024
CDE Solicits Comments on the Scope and Procedures for Filing Bioequiva...
10/21/2024
China Releases First National Guidelines for Obesity Diagnosis and Tre...
10/21/2024
China Sees Drop in Deaths from Chronic Diseases as Efforts Intensify A...
10/21/2024
CStone Announces Patent Publication for First-in-Class ADC CS5006
10/21/2024
USFDA Grants Fast Track Designation to Coherent Biopharma's CBP-1008
10/21/2024
Europe's Share of Global Clinical Trials Shrinks as China Gains Ground...
10/21/2024
NMPA Issues the Pilot Plan for Staged Production of Biological Product...
10/21/2024
Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Grant...
Page:
31
/
761
Total number of articles:
22830
:
[First]
[<<]
[29]
[30]
[31]
[32]
[33]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit